On June 29th, 2023, Infinity portfolio company "Laekna Inc." was successfully listed on the main board of the Hong Kong Stock Exchange. Stock code: 2105. The global offering of 63,728,000 shares, priced at HK $12.41 per share, raised approximately HK $791 million (approximately US $101 million).  The company has become the largest biotech company in Hong Kong IPO financing so far this year. 

Founded in 2016, Laekna Inc. is a clinical-stage biomedical technology company dedicated to solving the medical needs of cancers which has limited curative effect to standard of care (SOC).  The company currently has 2 core products and 14 other pipelines: The core product, LAE002, is an adenosine triphosphate (ATP)-competitive AKT inhibitor. Another core product, LAE001, is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2.  

The net proceeds from the listing will be used to rapidly advance the clinical development and approval of the company's core products LAE001 and LAE002, accelerate the research and development of other existing pipeline products, continuously promote and improve the company's pipeline products, increase production capacity and develop manufacturing capabilities, accelerate business development and strengthen global network. 



Infinity Capital completed its investment in Laekna Inc. in April 2022.  Dr. Lu Xiangyang, founder, chairman and CEO of the company, said: "The successful listing on the Hong Kong Stock Exchange means that Laekna has set foot on the stage of the international capital market. This is an important milestone in the development of the company, but also a new starting point.  Thanks to all employees of Laekna for their joint efforts and the support and trust given by all investors and partners.  We will continue to benefit patients, return shareholders and society, and strive to become a public enterprise with more market value and social responsibility.” 

Photo from Laekna Inc. Copyright belongs to the original author   

Infinity capital management co., ltd (hereinafter referred to as "Infinity Capital") is an equity investment subsidary of Huafa Group, a leading state-owned enterprise in Zhuhai and one of the top 500 China enterprises. It is also the core business entity of Infinity Group, a well-known investment management institution originating from Israel. It mainly operates domestic RMB fund business and cross-border investment business. It has been distributed in more than 10 cities forming five major business areas in North China, East China, South China, Southwest China, Hong Kong and overseas regions, in the fields of new energy, integrated circuits, big health, life sciences, advanced manufacturing, new materials and TMT.